Liver Fibrosis, FibroTest - Actitest
Label Mnemonic: | FIBRO |
Epic code: | LAB8382 |
Downtime form: | Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Commercial Mailout Laboratory
6240-8 RCP
356-8593
6240-8 RCP
356-8593
Specimen(s):
Serum
Specimen
Instructions:
1. Protect specimen from light.
2. Centrifuge and aliquot within 2 hours of collection.
2. Centrifuge and aliquot within 2 hours of collection.
Collection Medium:
![]() | and | ![]() |
Red top tube 5 mL (Clot Activator) | Red top tube 5 mL (Clot Activator) |
Minimum:
Draw TWO red top tubes.
Preferred Minimum: 3 mL serum
Absolute Minimum: 1.5 mL serum
Preferred Minimum: 3 mL serum
Absolute Minimum: 1.5 mL serum
Delivery Instructions:

Testing Schedule:
HAPTF, A2MF: Monday through Saturday; 3 p.m.
ALTF, GGTF, TBILF: Monday through Sunday; Continuously
APOAF: Monday through Saturday; Continuously
ALTF, GGTF, TBILF: Monday through Sunday; Continuously
APOAF: Monday through Saturday; Continuously
Turn Around
Time:
1 day upon receipt at reference laboratory
Reference Range:
FibroTest-ActiTest, Interpretation
ALPHA-2-MACROGLOBULIN
100-280 mg/dL
ALANINEAMINOTRANSFERASE (ALT)
Males:
<12 months: No established reference values
> or =1 year: 7-55 U/L
Females:
<12 months: No established reference values
> or =1 year: 7-45 U/L
APOLIPOPROTEIN A1
Males:
<24 months: No established reference values
2-17 years:
Low: <115 mg/dL
Borderline low: 115-120 mg/dL
Acceptable: >120 mg/dL
> or =18 years: > or =120 mg/dL
Females:
<24 months: No established reference values
2-17 years:
Low: <115 mg/dL
Borderline low: 115-120 mg/dL
Acceptable: >120 mg/dL
> or =18 years: > or =140 mg/dL
GAMMA-GLUTAMYLTRANSFERASE (GGT)
Males:
0-11 months: <178 U/L
12 months-6 years: <21 U/L
7-12 years: <24 U/L
13-17 years: <43 U/L
> or =18 years: 8-61 U/L
Females:
0-11 months: <178 U/L
12 months-6 years: <21 U/L
7-12 years: <24 U/L
13-17 years: <26 U/L
> or =18 years: 5-36 U/L
HAPTOGLOBIN
30-200 mg/dL
BILIRUBIN, TOTAL
0-6 days: Refer to www.bilitool.org for information on age-specific (postnatal hour of life) serum bilirubin values.
7-14 days: <15.0 mg/dL
15 days to 17 years: < or =1.0 mg/dL
> or =18 years: < or =1.2 mg/dL
FibroTest Score Stage Interpretation 0.00-0.21* F0 No fibrosis 0.21-0.27* F0-F1 No fibrosis 0.27-0.31* F1 Minimal fibrosis 0.31-0.48* F1-F2 Minimal fibrosis 0.48-0.58* F2 Moderate fibrosis 0.58-0.72* F3 Advanced fibrosis 0.72-0.74* F3-F4 Advanced fibrosis 0.74-1.00 F4 Severe fibrosis (Cirrhosis) *Boundary values can apply to 2 stages based on rounding. For example, a FibroTest score of 0.305 will round up to 0.31 and be staged F1. A FibroTest score of 0.314 will round down to 0.31 and be staged F1-F2. ActiTest Score Grade Interpretation 0.00-0.17* A0 No activity 0.17-0.29* A0-A1 No activity 0.29-0.36* A1 Minimal activity 0.36-0.52* A1-A2 Minimal activity 0.52-0.60* A2 Significant activity 0.60-0.62* A2-A3 Significant activity 0.62-0.100 A3 Severe activity*Boundary values can apply to 2 grades based on rounding. For example, an ActiTest score of 0.285 will round up to 0.29 and be graded A0-A1. An ActiTest score of 0.294 will round down to 0.29 be graded A1.
ALPHA-2-MACROGLOBULIN
100-280 mg/dL
ALANINEAMINOTRANSFERASE (ALT)
Males:
<12 months: No established reference values
> or =1 year: 7-55 U/L
Females:
<12 months: No established reference values
> or =1 year: 7-45 U/L
APOLIPOPROTEIN A1
Males:
<24 months: No established reference values
2-17 years:
Low: <115 mg/dL
Borderline low: 115-120 mg/dL
Acceptable: >120 mg/dL
> or =18 years: > or =120 mg/dL
Females:
<24 months: No established reference values
2-17 years:
Low: <115 mg/dL
Borderline low: 115-120 mg/dL
Acceptable: >120 mg/dL
> or =18 years: > or =140 mg/dL
GAMMA-GLUTAMYLTRANSFERASE (GGT)
Males:
0-11 months: <178 U/L
12 months-6 years: <21 U/L
7-12 years: <24 U/L
13-17 years: <43 U/L
> or =18 years: 8-61 U/L
Females:
0-11 months: <178 U/L
12 months-6 years: <21 U/L
7-12 years: <24 U/L
13-17 years: <26 U/L
> or =18 years: 5-36 U/L
HAPTOGLOBIN
30-200 mg/dL
BILIRUBIN, TOTAL
0-6 days: Refer to www.bilitool.org for information on age-specific (postnatal hour of life) serum bilirubin values.
7-14 days: <15.0 mg/dL
15 days to 17 years: < or =1.0 mg/dL
> or =18 years: < or =1.2 mg/dL
Interpretive Data:
FibroTest-ActiTest provides a score that assesses hepatic fibrosis (F0-
F4) and a score that assesses hepatic inflammatory activity (A0-A3).
Interpretation of the score is provided in the report. Individual
results from the 6 component tests are also provided with institution-
specific reference intervals.
Fibrosis is reported relative to a scale ranging from F0-F4 (F0=no fibrosis, F1=minimal fibrosis, F2=moderate fibrosis, F3=advanced fibrosis, F4=severe fibrosis). Fibrosis scores may overlap (eg, F0/F1, F1/F2).
Activity is reported relative to a scale ranging from A0-A3 (A0=no activity, A1=minimal activity, A2=significant activity, A3=severe activity). Activity scores may overlap (eg, A0/A1, A1/A2).
Fibrosis is reported relative to a scale ranging from F0-F4 (F0=no fibrosis, F1=minimal fibrosis, F2=moderate fibrosis, F3=advanced fibrosis, F4=severe fibrosis). Fibrosis scores may overlap (eg, F0/F1, F1/F2).
Activity is reported relative to a scale ranging from A0-A3 (A0=no activity, A1=minimal activity, A2=significant activity, A3=severe activity). Activity scores may overlap (eg, A0/A1, A1/A2).
Comments:
Useful For:
Evaluating hepatic fibrosis in chronic hepatitis C patients
Diagnosing fibrosis in carriers of chronic hepatitis B virus
Evaluating hepatic fibrosis in co-infected HIV carriers
Providing access to new-generation noninterferon treatment for hepatitis
Evaluating fibrosis in patients suffering from metabolic conditions (nonalcoholic fatty liver disease) and patients who consume excess alcohol
Evaluating hepatic fibrosis in chronic hepatitis C patients
Diagnosing fibrosis in carriers of chronic hepatitis B virus
Evaluating hepatic fibrosis in co-infected HIV carriers
Providing access to new-generation noninterferon treatment for hepatitis
Evaluating fibrosis in patients suffering from metabolic conditions (nonalcoholic fatty liver disease) and patients who consume excess alcohol
Methodology:
INTF: Algorithm and interpretation provided through
BioPredictive.
APOAF: Automated Turbidimetric Immunoassay
A2MF: Nephelometry
HAPTF: Nephelometry
ALTF: Photometric Rate, L-Alanine with Pyridoxal-5-Phosphate
GGTF: Photometric Rate
TBILF: Photometric, Diazonium Salt (DPD)
APOAF: Automated Turbidimetric Immunoassay
A2MF: Nephelometry
HAPTF: Nephelometry
ALTF: Photometric Rate, L-Alanine with Pyridoxal-5-Phosphate
GGTF: Photometric Rate
TBILF: Photometric, Diazonium Salt (DPD)
CPT Code:
81596